Entrada Therapeutics News and Activities

Presence

Entrada Therapeutics develops medicines for serious diseases. It provides intracellular therapy platforms, research services, and drug candidates for pharmaceutical partners, healthcare providers, and patients with genetic and neuromuscular conditions.

Entrada Therapeutics products and services overview:

Therapeutic platforms
Drug discovery
Genetic medicines
Neuromuscular therapies
Research partnerships

Revenue: ~$149 million

Employees: 210

Headquarters: Boston, United States (USA)

Entrada Therapeutics is one of the...

Entrada Therapeutics is a company listed under the stock ticker TRDA (US).

Executives

View the org chart displaying its 30 main executives

Most searched biographies at Entrada Therapeutics

Create your alert
to follow the executive moves at Entrada Therapeutics.

Biotechnology

Entrada Therapeutics has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
Tissium has just announced a $60 Million fundraising (posted on July 8 2026).